Results 81 to 90 of about 1,279 (113)

[Comorbidities in multiple sclerosis and their influence on the choice of treatment]. [PDF]

Rev Neurol
Barboza A, Sinay V, Alonso R, Carnero-Contentti E, Hryb J, Silva B, Tavolini D, Ysrraelit MC, Correale J.   +8 more
europepmc   +1 more source

[Usefulness of the Beck depression inventory in the diagnosis of depressive disorders in multiple sclerosis]. [PDF]

Rev Neurol
Aparicio-Castro E, Candeliere-Merlicco A, María Santa C, Villaverde-González R.   +3 more
europepmc   +1 more source

Anti-NMDA receptor encephalitis secondary to SARS-CoV-2 infection

Neurología (English Edition), 2020
G. Alvarez Bravo, L. Ramió i Torrentà
doaj   +1 more source

Risk of SARS-CoV-2 infection and clinical outcomes in multiple sclerosis patients in La Rioja (Spain): Riesgo de infección por SARS-CoV-2 y resultados clínicos en pacientes con esclerosis múltiple en la Rioja (España). [PDF]

Med Clin (Engl Ed), 2020
Castillo Álvarez F, López Pérez MÁ, Marzo Sola ME.   +2 more
europepmc   +1 more source

[Therapeutic attitudes towards multiple sclerosis in Central America and the Caribbean facing the SARS-CoV-2 pandemia]. [PDF]

Neurologia (Engl Ed), 2020
Rivera VM, Gracia F, Díaz A.
europepmc   +1 more source

Influence of manipulative skills on quality of life and activities of daily living in multiple sclerosis. [PDF]

Rev Neurol
Rodríguez-Menéndez S, Martínez-Piédrola RM, Menéndez-González M, Pérez-de-Heredia-Torres M.   +3 more
europepmc   +1 more source

Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile. [PDF]

Arq Neuropsiquiatr, 2021
Ysrraelit MC, Caride A, Sinay V, Rivera Kindel M, Halfon MJ, Patrucco L, Piedrabuena R, Diaz Aragunde VE.   +7 more
europepmc   +1 more source